In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
|Videos|August 25, 2015
What Does the Future Hold for Biosimilars in the United States?
Author(s)Davy James, Managing Editor
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.
Advertisement
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.
Advertisement
Related to this article
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Preparing Pharmacists for Psychedelic Medicine
2
National Pharmacy Technician Day: Celebrating the Backbone of Pharmacy
3
Cemdisiran’s Potential to Reduce Hospitalizations in Myasthenia Gravis
4
Supporting Patients Prescribed Opioids in the Era of “Fentanyl Free America”
5